Weight Management Profile – GLP-1 / GIP-GLP-1 Monitoring at 3–6 Months
Available with home visit Weight Management Profile – GLP-1 / GIP-GLP-1 Monitoring is a comprehensive monitoring package, generally recommended 3–6 months after initiation of weight management treatment, designed to assess carbohydrate metabolism, liver and kidney function, as well as key hematological and nutritional parameters.
The results allow the physician to assess the metabolic response, treatment tolerability and the need for additional investigations. The package does not rule out all adverse reactions and does not replace regular clinical assessment.
Monitoring is relevant because GLP-1/GIP-GLP-1 therapies may significantly affect glycemic control, while gastrointestinal reactions may lead to fluid loss and secondary impairment of kidney function.
Components
| Investigation group | Included tests | What it evaluates |
| Hematological and inflammatory assessment | Complete blood count (without ESR); Erythrocyte sedimentation rate (ESR); C-reactive protein (CRP) | Key hematological parameters and nonspecific markers of inflammation |
| Carbohydrate metabolism | Glucose; Glycated hemoglobin (HbA1c) | Current blood glucose level and longer-term glycemic control |
| Liver and biliary function | ALT; AST; GGT; Alkaline phosphatase (ALP) | Key biochemical hepatic and hepatobiliary markers |
| Kidney function | eGFR (CKD-EPI) + Serum creatinine | Renal filtration function |
| Nutritional status and mineral metabolism | Vitamin B12; Vitamin D (25-OH vitamin D); Folic acid; Total serum calcium | The status of selected vitamins and mineral metabolism |
Role of the investigation
PRF100 is designed for periodic biological monitoring of patients receiving medical treatment for weight management.
The profile allows comparison of results with baseline values and may help the physician assess changes in carbohydrate metabolism, liver and kidney function, hematological status and selected nutritional parameters.
Indications
It is intended for patients receiving, on the recommendation of a physician, pharmacological treatment for weight management, including therapies with GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists.
It may be used for periodic monitoring after treatment initiation, following a dose adjustment or at intervals individually determined by the physician.
The patient should immediately inform the physician in case of severe or persistent abdominal pain, repeated vomiting, dehydration, jaundice or other significant symptoms occurring during treatment.
Severe and persistent abdominal pain requires medical evaluation as it may be a sign of acute pancreatitis.
Procedure
A venous blood sample is collected for the hematological and biochemical tests included in the profile.
Where possible, the results are compared with values obtained before treatment and interpreted by the physician in relation to the clinical course, changes in body weight, administered dose, treatment tolerability and any concomitant therapies.
Medical sources:
https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf
https://www.ncbi.nlm.nih.gov/books/NBK611612/
https://pubmed.ncbi.nlm.nih.gov/39632534/
https://library.usmf.md/sites/default/files/2025-02/Ghid%20practic%20pentru%20evaluarea%20si%20tratamentul%20adultilor%20cu%20obezitate.pdf
Preparation:
- Sample collection is recommended in the morning, on an empty stomach, after 8–12 hours of fasting; plain water is permitted.
- Approximately 24 hours before sample collection, it is recommended to avoid alcohol and intense physical exercise. On the morning of sample collection, coffee, tea, sweetened beverages and smoking should be avoided.
- The patient should inform the medical staff about GLP-1/GIP-GLP-1 treatment, the dose being used, and any other medications and supplements being taken.
- Prescribed medication should not be discontinued or modified without medical advice before sample collection.
- Maintaining adequate hydration is important, especially for patients experiencing nausea, vomiting or diarrhea during treatment.
Services in package:
1 day 1 day 1 day 1 day 1 day 1 day 1 day 1 day 1 day 1 day 1 day 1 day 1 day 1 day 
